Officials at Taiwan-based Bora Pharmaceuticals said the company made a strategic investment whereby Bora Biologics, a wholly-owned subsidiary of Bora and specialist large molecule CDMO, and Tanvex, also in Taiwan, will combine their biomanufacturing facilities to offer global services for biologics development and supply.
The investment will bring together Bora’s CDMO capabilities with Tanvex’s scale, development skills, and FDA-approved commercial-scale facility in San Diego, according to Bora. Bobby Sheng, chairman, and CEO of the Bora Group, will serve as chairman of the merged organization.
Upon completion of the transaction, which is expected in Q1 of 2025, Bora, will hold approximately 30.5% of Tanvex’s total outstanding shares.
Ten CDMO facilities around the globe
Bora Pharmaceuticals runs ten CDMO facilities worldwide and will collaborate with Tanvex, which has a new fill/finish facility in Maryland, to leverage its global CDMO operations to provide services to customers. Tanvex brings over 100,000 ft2 of biomanufacturing space and 1,000-L bioreactors, which complement Bora’s 500-L bioreactors to provide a scalable service offering, noted Sheng.
“This strategic investment focuses on both parties’ shared vision for the biologics CDMO business,” continued Sheng. “This partnership will enable the combined entity to rapidly respond to evolving industry demands and policy developments, such as the BIOSECURE Act in the United States, and capitalize on new opportunities in onshoring, friendshoring, and the growing CDMO demands driven by these policy changes.”
“Tanvex offers an integrated suite of services from early-stage non-GMP preclinical development to commercial-stage CGMP manufacturing,” added Henry Chen, chairman, and CEO of Tanvex. “The strategic investment by Bora presents an optimal opportunity to combine our strengths with Bora’s global CDMO platform.”
